Georgia Bio Statement on BD Sterilization Plant In Georgia

Closure May Lead to Medical Device Shortage & Impact Patients

October 25, 2019 06:06 PM Eastern Daylight Time

ATLANTA–( BUSINESS WIRE )–Georgia Bio member companies are dedicated to improving patients’ lives-enhancing patient safety and expanding patient access to innovative treatments. Public health and environmental protection are central to the values of the life sciences community. Our member companies continually strive to exceed regulations and reduce their environmental footprint.

We are very concerned with the potential shut down of BD’s Covington facility over the use of EtO. Ethylene oxide is the safest, and sometimes, only method for ensuring the sterilization of medical devices for clinicians and patients. Approximately 50% of all medical devices are sterilized using EtO, accounting for more than 20 billion devices annually in the U.S. Many of our members manufacture devices and products that cannot be sterilized by any other means due to their complex nature, including pacemakers, implantable defibrillators, cardiac catheters, biopsy instruments and surgical fixation devices and vascular access devices including PICCs, midlines and ports. BD is the largest supplier of urinary catheters that are used in almost every surgical procedure that takes longer than 2 hours. They are also one of the only suppliers for pediatric vascular access devices used to deliver chemotherapy to children with cancer.

Georgia Bio believes policy makers have an obligation to protect the public from harmful emissions from any source, and we believe all industrial facilities in our state should meet or exceed safety standards. We support an open and transparent debate regarding EtO that is grounded in scientific fact, but caution that a hasty decision to close this facility or severely restrict the use of ethylene oxide would endanger the health of thousands, possibly even millions, of patients who are relying on sterile medical products.

About Georgia Bio

Georgia Bio is an independent, non-profit 501(c)(3) trade association whose mission is to advance the growth of Georgia’s life sciences industry and foster strategic partnerships that can create a healthier world. Georgia Bio member companies are dedicated to improving patients’ lives – enhancing patient safety and expanding patient access to innovative treatments. Public health and environmental protection are central to the values of the life sciences community. Georgia Bio members include bioscience and medtech companies, academic and research institutions, life science service providers, digital health companies, and related organizations. For more information, visit  www.gabio.org  or follow us on  Twitter @Georgia_Bio.

Contacts

Joseph Santoro 
404-334-7538 
jsantoro@gabio.org

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS